Johnson & Johnson $JNJ Stock Position Raised by Braun Stacey Associates Inc.

Braun Stacey Associates Inc. lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 9.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 148,856 shares of the company’s stock after acquiring an additional 13,411 shares during the quarter. Johnson & Johnson accounts for 1.0% of Braun Stacey Associates Inc.’s portfolio, making the stock its 29th largest holding. Braun Stacey Associates Inc.’s holdings in Johnson & Johnson were worth $30,806,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also modified their holdings of the stock. Ethos Financial Group LLC boosted its stake in shares of Johnson & Johnson by 13.9% during the 4th quarter. Ethos Financial Group LLC now owns 10,377 shares of the company’s stock worth $2,147,000 after acquiring an additional 1,267 shares in the last quarter. Signaturefd LLC boosted its stake in shares of Johnson & Johnson by 7.9% during the 4th quarter. Signaturefd LLC now owns 63,858 shares of the company’s stock worth $13,215,000 after acquiring an additional 4,674 shares in the last quarter. Ascent Group LLC boosted its stake in shares of Johnson & Johnson by 7.2% during the 4th quarter. Ascent Group LLC now owns 68,009 shares of the company’s stock worth $14,074,000 after acquiring an additional 4,560 shares in the last quarter. Sylvest Advisors LLC boosted its stake in shares of Johnson & Johnson by 2.1% during the 4th quarter. Sylvest Advisors LLC now owns 5,951 shares of the company’s stock worth $1,232,000 after acquiring an additional 125 shares in the last quarter. Finally, JB Capital LLC boosted its stake in shares of Johnson & Johnson by 1.6% during the 4th quarter. JB Capital LLC now owns 9,145 shares of the company’s stock worth $1,893,000 after acquiring an additional 147 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Price Performance

JNJ opened at $238.47 on Wednesday. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.48. Johnson & Johnson has a 12-month low of $141.50 and a 12-month high of $251.71. The stock has a fifty day moving average of $240.53 and a 200-day moving average of $214.17. The firm has a market capitalization of $574.38 billion, a P/E ratio of 21.58, a PEG ratio of 2.41 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The business had revenue of $24.28 billion during the quarter. Equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the sale, the executive vice president directly owned 23,003 shares in the company, valued at approximately $5,598,700.17. This trade represents a 21.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Timothy Schmid sold 1,322 shares of the stock in a transaction on Friday, February 20th. The stock was sold at an average price of $245.66, for a total value of $324,762.52. Following the sale, the executive vice president owned 25,447 shares of the company’s stock, valued at approximately $6,251,310.02. This represents a 4.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 30,142 shares of company stock valued at $7,360,528. 0.16% of the stock is owned by corporate insiders.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Citigroup raised its price target to $285 and kept a “buy” rating, implying roughly 20% upside from recent levels — a notable analyst vote of confidence for JNJ’s outlook. Read More.
• Positive Sentiment: Guggenheim also nudged up its target to $244 and maintained a “buy” rating, adding incremental analyst support for the stock. Read More.
• Positive Sentiment: JNJ received CE‑Mark clearance and launched the next‑gen VARIPULSE Pro PFA catheter in Europe — a commercial milestone that should support MedTech sales growth in international markets. Read More.
• Positive Sentiment: Specialty therapy updates: JNJ secured a permanent US reimbursement code for bladder cancer drug INLEXZO, reported 52‑week efficacy for ICOTYDE in psoriasis, and struck an exclusive Japan distribution deal for SIRTURO (drug‑resistant TB). These moves improve commercial visibility and address previous undervaluation arguments. Read More.
• Neutral Sentiment: Technical / timing note: Dow Jones/Investors.com flagged JNJ as in or near a buy zone — bullish from a trading setup perspective but not a fundamental catalyst. Read More.
• Neutral Sentiment: Analyst consensus remains around “Moderate Buy,” reflecting broad analyst support but not unanimous enthusiasm; watch for further analyst commentary and earnings updates. Read More.
• Neutral Sentiment: Longer‑term comparison pieces (e.g., JNJ vs KO) highlight JNJ’s dividend durability and oncology growth but don’t present immediate price catalysts. Read More.

Analyst Ratings Changes

A number of research firms have recently issued reports on JNJ. Freedom Capital lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Friday, January 16th. Scotiabank restated an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, January 22nd. Sanford C. Bernstein increased their target price on Johnson & Johnson from $208.00 to $225.00 and gave the company a “market perform” rating in a report on Friday, January 23rd. TD Cowen increased their target price on Johnson & Johnson from $222.00 to $250.00 and gave the company a “buy” rating in a report on Thursday, January 22nd. Finally, Wall Street Zen lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $237.57.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.